Back to mobile site

Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

August 14, 2026 4:32 PM EDT





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.


SCHEDULE 13G



 
Frazier Life Sciences Public Fund, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:08/14/2026
 
FHMLSP, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:08/14/2026
 
FHMLSP, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:08/14/2026
 
Frazier Life Sciences XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:08/14/2026
 
FHMLS XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:08/14/2026
 
FHMLS XI, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:08/14/2026
 
Frazier Life Sciences XII, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:08/14/2026
 
FHMLS XII, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:08/14/2026
 
FHMLS XII, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:08/14/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G filed on December 19, 2025)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13G